Figure 1

The Canadian Association of Gastroenterology clinical practice guideline provides an evidence-based framework for managing irritable bowel syndrome, covering diagnosis, dietary modifications, pharmacological treatments, and psychological interventions.

Figure 3

Evidence evaluation for probiotic therapies in IBS suggests overall benefit, particularly with combination probiotic preparations. Strain-specific recommendations remain difficult due to heterogeneity in study designs and products evaluated.

Figure 4

Dietary interventions for IBS include the low-FODMAP diet, which has demonstrated efficacy in reducing bloating, abdominal pain, and altered bowel habits. A dietitian-guided three-phase approach (restriction, reintroduction, personalization) is recommended.

Figure 5

Polyethylene glycol 3350 is evaluated for IBS with constipation based on two RCTs totaling 181 patients. Evidence supports its use for improving stool consistency, though effects on abdominal pain are less consistent.

Figure 6

Antispasmodic agents including peppermint oil, pinaverium, and trimebutine receive conditional recommendations for IBS symptom management. Evidence quality varies across specific agents.

Figure 7

An algorithmic approach to IBS management stratifies treatment by predominant bowel habit (IBS-C, IBS-D, IBS-M) and symptom severity. First-line interventions include dietary modification and fiber supplementation.